Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

[1]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[2]  A. Sapino,et al.  Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors , 2022, npj Precision Oncology.

[3]  J. Chan,et al.  The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer , 2021, JAMA network open.

[4]  C. Perou,et al.  Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer , 2021, Cancer Research.

[5]  C. Sotiriou,et al.  HER2-Low Breast Cancer: Molecular Characteristics and Prognosis , 2021, Cancers.

[6]  J. Guan,et al.  Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer , 2021, Cell reports.

[7]  A. Lluch,et al.  Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.

[8]  H. Rugo,et al.  Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  K. Hughes,et al.  Disease Spectrum of Breast Cancer Susceptibility Genes , 2020, Frontiers in Oncology.

[10]  F. Cardoso,et al.  HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Sapino,et al.  Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. , 2020, Seminars in cancer biology.

[12]  C. Redfern,et al.  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. D. de Vries,et al.  Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.

[15]  C. Sotiriou,et al.  Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  N. Schultz,et al.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[18]  A. Vincent-Salomon,et al.  The Dilemma of HER2 Double-equivocal Breast Carcinomas , 2018, The American journal of surgical pathology.

[19]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[20]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[22]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[23]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[24]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[25]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[26]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[27]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[28]  Renaud Gaujoux,et al.  A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.

[29]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Kauraniemi,et al.  Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.

[31]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..